Bacteriophage Production in Compliance with Regulatory Requirements

Jean Paul Pirnay, Maia Merabishvili, Daniel De Vos, Gilbert Verbeken

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

In this chapter, we discuss production requirements for therapeutic bacteriophage preparations. We review the current regulatory expectancies and focus on pragmatic production processes, implementing relevant controls to ensure the quality, safety, and efficacy of the final products. The information disclosed in this chapter can also serve as a basis for discussions with competent authorities regarding the implementation of expedited bacteriophage product development and licensing pathways, taking into account some peculiarities of bacteriophages (as compared to conventional medicines), such as their specificity for, and co-evolution with, their bacterial hosts. To maximize the potential of bacteriophages as natural controllers of bacterial populations, the implemented regulatory frameworks and manufacturing processes should not only cater to defined bacteriophage products. But, they should also facilitate personalized approaches in which bacteriophages are selected ad hoc and even trained to target the patient’s infecting bacterial strain(s), whether or not in combination with other antimicrobials such as antibiotics.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages89-115
Number of pages27
DOIs
Publication statusPublished - 2024

Publication series

NameMethods in Molecular Biology
Volume2734
ISSN (Print)1064-3745
ISSN (Electronic)1940-6029

Keywords

  • Antibiotic resistance
  • Bacteriophage therapy
  • Drug
  • Manufacturing
  • Medicinal product
  • Production
  • Quality and safety

Fingerprint

Dive into the research topics of 'Bacteriophage Production in Compliance with Regulatory Requirements'. Together they form a unique fingerprint.

Cite this